prostate cancer
Conditions
Interventions
prostate cancer patient:None
Sponsors
Chengdu Integrated TCM and Western Medicine Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Cases with a previous pathological diagnosis of prostate cancer; 2. Available FFPE prostate cancer tissue samples from which consecutive tissue sections can be prepared for this study; 3. Tissue samples with adequate preservation quality and intact tissue structure, suitable for immunohistochemistry and multiplex immunofluorescence analyses; 4. Available clinicopathological information relevant to this study, including but not limited to Gleason score, tumor stage, metastatic status, PSA level, lesion extent, or histological subtype; 5. Samples and related data have been de-identified or coded, and their use is within the scope of ethics approval or ethics filing;
Exclusion criteria
Exclusion criteria: 1. Non-prostate cancer cases or cases without a definite pathological diagnosis; 2. FFPE tissue samples with poor preservation quality, severe tissue damage, section detachment, or extensive necrosis, making them unsuitable for immunohistochemistry or multiplex immunofluorescence analyses; 3. Cases with insufficient consecutive tissue sections to complete the planned study assays; 4. Cases with missing key clinicopathological information required for the main correlation analyses; 5. Samples with unclear numbering, source, or transfer information, preventing the establishment of a traceable but de-identified correspondence; 6. Samples not covered by the ethics approval or ethics filing, or samples from patients who explicitly refused the use of their specimens for research;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subcellular localization of G protein-coupled receptor 107 (GPR107) protein and its specific post-translational modification site in prostate cancer tissues;Expression level of G protein-coupled receptor 107 (GPR107) protein in prostate cancer tissues;Expression level of the specific post-translational modification site of G protein-coupled receptor 107 (GPR107) in prostate cancer tissues;Expression trends of G protein-coupled receptor 107 (GPR107) and its specific post-translational modification site across pathological subgroups;Tumor staging; metastatic status;Co-expression of G protein-coupled receptor 107 (GPR107), its specific post-translational modification site, and key target proteins in prostate cancer tissues;Spatial co-localization of G protein-coupled receptor 107 (GPR107), its specific post-translational modification site, and key target proteins in prostate cancer tissues; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inter-case differences in the expression level of G protein-coupled receptor 107 (GPR107) protein;Expression trends of G protein-coupled receptor 107 (GPR107) and its specific post-translational modification site across pathological subgroups;Staining specificity, stability, and applicability of the relevant antibodies in formalin-fixed paraffin-embedded (FFPE) prostate cancer tissues;Spatial distribution pattern of target molecules in prostate cancer tissues based on multiplex immunofluorescence (mIF) images; | — |
Countries
China
Contacts
Public ContactLiang Yuqing
Chengdu Integrated Traditional Chinese and Western Medicine Hospital
Outcome results
None listed